Pathophysiological Studies of Monoaminergic Neurotransmission Systems in Valproic Acid-Induced Model of Autism Spectrum Disorder

Hsiao-Ying Kuo 1,* and Fu-Chin Liu 2,*

1 Institute of Anatomy and Cell Biology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan
2 Institute of Neuroscience, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan
* Correspondence: kuohy@nycu.edu.tw (H.-Y.K.); fuchin@nycu.edu.tw (F.-C.L.);
Tel.: +886-2-2826-7075 (H.-Y.K.); +886-2-2826-7216 (F.-C.L.); Fax: +886-2-2821-2884 (H.-Y.K.);
+886-2-2820-0259 (F.-C.L.)

Abstract: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with complex etiology. The core syndromes of ASD are deficits in social communication and self-restricted interests and repetitive behaviors. Social communication relies on the proper integration of sensory and motor functions, which is tightly interwoven with the limbic function of reward, motivation, and emotion in the brain. Monoamine neurotransmitters, including serotonin, dopamine, and norepinephrine, are key players in the modulation of neuronal activity. Owing to their broad distribution, the monoamine neurotransmitter systems are well suited to modulate social communication by coordinating sensory, motor, and limbic systems in different brain regions. The complex and diverse functions of monoamine neurotransmission thus render themselves as primary targets of pathophysiological investigation of the etiology of ASD. Clinical studies have reported that children with maternal exposure to valproic acid (VPA) have an increased risk of developing ASD. Extensive animal studies have confirmed that maternal treatments of VPA include ASD-like phenotypes, including impaired social communication and repetitive behavior. Here, given that ASD is a neurodevelopmental disorder, we begin with an overview of the neural development of monoaminergic systems with their neurochemical properties in the brain. We then review and discuss the evidence of human clinical and animal model studies of ASD with a focus on the VPA-induced pathophysiology of monoamine neurotransmitter systems. We also review the potential interactions of microbiota and monoamine neurotransmitter systems in ASD pathophysiology. Widespread and complex changes in monoamine neurotransmitters are detected in the brains of human patients with ASD and validated in animal models. ASD animal models are not only essential to the characterization of pathogenic mechanisms, but also provide a preclinical platform for developing therapeutic approaches to ASD.

Keywords: valproic acid; autism spectrum disorder; serotonin; dopamine; norepinephrine; histamine; neurodevelopment

1. Introduction

Autism spectrum disorder (ASD) is a devastating neurodevelopmental disease with an increasing prevalence of ~18.5 per 1000 people [1]. The etiology of ASD is highly heterogeneous with genetic and environmental roots. The core syndromes of ASD patients are deficits in social communication/interaction and restrictive/repetitive behavior [2]. Because of its complicated and heterogeneous etiology, the pathological mechanisms are not yet fully characterized, which prevents the development of effective therapy for ASD.

1.1. Animal Models of ASD

ASD is a complex and heterogeneous neurodevelopmental disorder. Genetic mutations of genes involved in synaptic wiring and neurotransmission in the development and
function of neural circuits have been linked to ASD pathogenesis [3,4]. Genetic animal models of ASD provide research platforms to investigate ASD pathophysiology caused by mutations of ASD-risk genes, including MECP2, SHANK3, NLGN3, etc. [3–5]. As developing brains are vulnerable to environmental insults, environmental factors also play a significant role in the pathogenesis of ASD. It has been estimated up to 40–50% of the variance in ASD pathogenesis is influenced by environmental factors [6]. Maternal exposure to pharmacological reagents, heavy metals, and vaccination against virus infection has been implicated in the etiology of ASD [6].

1.2. VPA-Induced ASD-Like Animal Models

Valproic acid (VPA) is prescribed medicine for treating epilepsy, migraine, and mood disorders [7]. However, clinical studies indicate that children with maternal exposure to VPA have a higher chance of developing ASD [8]. Subsequent animal studies confirm that maternally VPA-treated offspring develop prominent ASD-like phenotypes resembling the core syndromes of human ASD patients.

Most VPA-induced animal models are established in the rodent owing to the easy accessibility to rodents in the laboratory setting. VPA-induced models have also been reported in non-human primates [9,10]. The time windows of VPA administration in producing offspring with ASD-like phenotypes are from neural tube closure to neurogenesis, i.e., embryonic (E) day 9-E12.5 in pregnant rats (Tables 1 and 2) [11–13]. Time windows of VPA exposure appear to critically influence the developmental consequences in the VPA models. Previous studies have compared the teratogenic effects of VPA in different time windows of exposure. For example, Rodier et al. have found that VPA exposure at E11.5, E12, or E12.5 results in differential vulnerabilities of cranial nerves in the brains of offspring [13]. Animals exposed to VPA at different gestational time windows also show distinct developmental trajectories and abnormalities in cortical and brainstem regions [14]. At the behavioral level, Kim et al. have reported that VPA exposure at E12, but not at E7, E9.5, and E15, causes significant ASD-like social abnormalities, suggesting that E12 is a critical period for inducing ASD-like phenotypes [15].

Intriguingly, postnatal VPA administration during the first two weeks after birth causes ASD-like behavioral phenotypes in rodents as well [16–18], suggesting that postnatal developmental processes, including synaptogenesis, myelination, and synaptic pruning are also vulnerable to VPA exposure. Therefore, ASD-like phenotypes could be induced by VPA administered at either gestational or early postnatal stages.

Regarding the issue of gender, the prevalence of human ASD patients among males is ~4.3 times higher than among females [1]. Most studies use male animals in VPA-induced ASD model studies. However, some groups also include females and found ASD phenotypes in female animals as well (Tables 1 and 2). To investigate sexual dimorphism of VPA effects, several studies have compared gender-specific alterations in maternally VPA-treated offspring [19–23]. Evidence shows gender-specific changes in the immune responses [19,20,22,24], cell density of cerebellum [23,25], network connectivity [26], anandamide signaling [27], attentional processing [28], and composition of gut microbiota [29] in maternally VPA-treated animal offspring. These sexual dimorphisms may be related to histone deacetylase (HDAC) inhibition by VPA, as Konopko et al. have reported differential epigenetic modification of Bdnf genes in maternally VPA-treated fetal brains of different genders [24]. In general, maternally VPA-treated male offspring have more severe ASD-like phenotypes compared to female offspring.

With respect to the dosage of VPA administration, maternal VPA exposure affects the nervous systems in a dose-dependent manner. Magnetic resonance imaging (MRI) studies have shown dose-dependent changes in networks of the primary motor cortex-premotor cortex and the primary motor cortex-supplementary motor area in humans, suggesting that VPA induces changes in specific neural circuits [30,31]. The higher dose of the expecting mother taking VPA, the higher risk of the offspring being diagnosed with ASD [32]. Frisch et al. have reported that offspring of rat dams receiving a high dose...
of VPA (720 mg/kg) daily during the entire pregnancy show the most severe phenotype of impaired learning and memory. In the same study, MRI data show that compared to a medium dose of VPA (470 mg/kg), the higher dose of maternal treatment of VPA (720 mg/kg) induced more significant reductions in cortical and brainstem regions of offspring [33]. Prenatal administration of a lower dose of VPA (200 mg/kg) did not induce ASD-like behavioral phenotypes [16]. Therefore, for the experimental induction of ASD-like behavioral phenotypes without severe developmental retardation in the offspring, VPA administrated at the dosage of 300–600 mg/kg in pregnant rodents and non-human primates are mostly used (Tables 1 and 2) [9,34–37].

1.3. Potential Mechanisms Underlying VPA-Induced ASD-Like Pathophysiology

It is yet unclear how maternal VPA exposure induces ASD pathophysiology. VPA is known to have multiple pharmacological properties. Firstly, VPA is a simple branched-chain fatty acid (2-propylpentanoic acid) that can directly inhibit voltage-gated sodium channels and suppress the high-frequency firing activity of neurons. VPA also can indirectly inhibit GABA transferase resulting in increased GABA neurotransmission in the brain [38]. Note that the imbalanced excitatory/inhibitory (E/I) ratio in neural circuits has been proposed as a prevailing pathogenic mechanism of ASD [39,40]. Hence, VPA may reduce the excitability of neural circuits by inhibiting GABA uptake, leading to disrupted E/I balance, which may account for ASD phenotypes. In supporting this hypothesis, previous studies show that abnormal E/I balance and aberrant synaptic transmission have been found in the medial prefrontal cortex (mPFC), primary somatosensory cortex, amygdala, and dorsal raphe nucleus of maternally VPA-treated rodent offspring [41–46]. Furthermore, drugs that regulate neuronal excitability can partially rescue ASD-like phenotypes in VPA-treated animals [37,47], suggesting that E/I imbalance resulting from VPA treatment may be a key mechanism of ASD pathogenesis.

Secondly, VPA functions as a non-specific histone deacetylase (HDAC) inhibitor that can affect neural development by chromosome remodeling [6–8]. VPA-induced changes in neural development have been reported in many studies and discussed by several review articles [12,35,48]. The epigenetic effects of VPA have been confirmed by VPA-induced site-specific epigenetic alterations in rodents [49–51] and non-human primates [9], suggesting that VPA-mediated epigenetic modifications may contribute to VPA-induced ASD-like pathophysiology. Several genome-wide screening studies have identified the alteration of genetic networks by VPA. In non-human primates, prenatal VPA administration changes the expression of human ASD-associated genes and the gene expression patterns that are related to synaptogenesis, critical period, neural plasticity, and E/I balance, including CADM1, LRRTM4, GRIN1, and GRIN2A in marmoset infant brains [52]. Another RNA sequencing study has investigated transcriptome profiles in maternal VPA-treated marmoset embryos and found marked alterations in the gene expression pattern of neuronal development, including axon guidance and calcium signaling [9]. In rodent models, maternal VPA treatment induces changes in circadian rhythm- and extracellular matrix-related genes in the mPFC [53]. Altered gene expression profiles in neural development and function, cellular development and function, cell death, and immune system are also detected in the amygdala of maternally VPA-treated offspring brains [54]. Proteomics study has further found changes in protein expression profiles in synaptic function, energy metabolism, cytoskeleton and neuropsychiatric disorders in the cerebral cortex of maternally VPA-treated rat offspring [55]. Note that molecular and cellular changes in the VPA-induced animal models are similar, but not identical to those in idiopathic ASD patients.

On the other hand, VPA-induced changes in the immune system are of particular interest, because maternal immune activation during embryonic stages has been proposed as a pathogenic mechanism of ASD [56]. Inflammatory responses are detected in human ASD brains, including elevated levels of inflammatory biomarkers and activation of astrocytes and microglia [57]. Evidence suggests abnormalities in the interaction of the microbiota-gut-brain axis and the immune system in ASD brains [58], highlighting the multifaceted
and potential pathogenic role of inflammation in ASD pathogenesis. In VPA-treated animals, marked signs of neuroinflammation have been detected, including elevated levels of reactive oxygen species, NFκB, and pro-inflammatory cytokines [59]. Moreover, anti-inflammatory drugs could alleviate ASD-like phenotypes in maternally VPA-treated animal offspring [37,47]. In light of these findings, we will discuss how monoamines interplay with the microbiota–gut–brain axis and the immune system later.

1.4. Advantages and Limitations of VPA-Induced ASD-Like Animal Models

Since the first rodent model in the 1970s, VPA exposure in experimental animals has been widely used as an ASD model to study the ASD etiology of environmental risk factors. The major advantage of studying VPA models is that the VPA-exposed animals develop robust ASD-like phenotypes resembling the core symptoms of ASD patients [7,11,12,35]. Its simple experimental protocols also allow it to be widely adopted as an animal model for studying ASD pathophysiology from molecular, cellular to behavioral levels for decades [12,35,48,60,61]. Moreover, as VPA is an HDAC inhibitor that can influence chromosome remodeling, VPA animal models may help understand the epigenetic basis of ASD etiology.

The limitations of VPA models are, however, that VPA exposure is one of many environmental risk factors of ASD and maternally VPA-exposed ASD patients represent a small population of ASD. The VPA-induced pathophysiology may thus account for part of ASD pathophysiology. Nonetheless, because VPA-induced pathophysiology shares some similarities with ASD genetic mutation models, e.g., synaptopathy [4,62], the easy accessibility and the extensive knowledge built on this ASD model have been leveraged to screen for pharmacological reagents for treating ASD patients [37,47,63].

1.5. Dysfunction of Monoaminergic Neurotransmission in VPA-Induced ASD-Like Animal Models of ASD

Alterations of monoaminergic neurotransmitter systems have been detected in many brain regions as well as in the peripheral system in ASD pathophysiology (Figure 1; Tables 1 and 2). Unlike the classical neurotransmitters of glutamate and GABA that directly dictate neuronal activity, monoamines are neuromodulators that modulate the excitability of neurons by regulating synaptic neurotransmission (Figure 2; Tables 1 and 2).

Monoamine-modulating drugs are so far the available medications for treating ASD-associated syndromes. The atypical antipsychotics, risperidone and aripiprazole, are U.S. Food and Drug Administration (FDA)-approved clinical drugs for ASD. Risperidone and aripiprazole pharmacologically act on dopamine (DA) and serotonin of the monoaminergic systems. In supporting the importance of the monoaminergic systems for ASD, several studies have shown that antipsychotics targeting monoaminergic systems are effective in improving maternal VPA-induced ASD-like abnormalities [64–67].

The neural development of monoaminergic systems protracts a long time from embryonic to postnatal stages. The prolonged developmental time frame makes it vulnerable to pathological alterations that are induced by genetic and epigenetic challenges related to ASD. In the present review, we focus on the VPA-induced ASD model, because it has been widely adopted to investigate the neuropathophysiology of ASD and used as an experimental platform to develop therapeutic reagents [35,37,68]. We begin with an overview of the neural development and neurochemical property of each monoamine neurotransmitter, we then discuss the abnormalities of ASD in human patients and VPA-induced animal models. Schematic summary of the monoaminergic neurotransmission-related endophenotypes and other pathophysiological changes in the central nervous system and peripheral system of VPA-treated animals are illustrated in Figures 1 and 2 and listed in Tables 1 and 2. Schematic drawings of synaptic transmission of monoaminergic neurotransmissions and VPA-induced dysfunction of monoaminergic neurotransmission are illustrated in Figure 2.
Figure 1. Alterations of monoaminergic systems in the brain and peripheral system of maternally VPA-treated rodent offspring. Schematic drawings illustrate pathophysiological changes in monoaminergic systems in the central nervous system and peripheral system of maternally VPA-treated rodent offspring. The bi-directional arrows indicate cross-talk between the central and peripheral systems. Abbreviations: ↑, increased; ↓, decreased; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine (serotonin); 5-HTP, 5-hydroxytryptophan; D1R, dopamine D1 receptor; D2R, dopamine D2 receptor; DAT, dopamine transporter; DOPAC, 3,4-dihydroxyphenylacetic acid; E/I, excitatory/inhibitory; Htr, 5-hydroxytryptamine receptors; mEPSCs, miniature excitatory postsynaptic currents; METH, methamphetamine; MHB, midbrain-hindbrain boundary; NET, norepinephrine transporter; SERT, serotonin transporter; SN, substantia nigra; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; VTA, ventral tegmental area.
Figure 2. Schematic drawings illustrate monoaminergic neurotransmissions and their dysregulation in response to maternal VPA challenge. (A) Serotonergic neurotransmission. (B) Dopaminergic neurotransmission. (C) Norepinephrinergic neurotransmission. The neurotransmission molecules that are altered by maternal VPA treatments are indicated by asterisk*. Abbreviations: ↑, increased; ↓, decreased; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HIAL: 5-hydroxyindole acetaldehyde; 5-HT, 5-hydroxytryptamine (serotonin); 5-HTP, 5-hydroxytryptophan; 5-HTR, 5-hydroxytryptamine receptor; AADC, aromatic L-amino acid decarboxylase; ALDH, aldehyde dehydrogenase; D1R, dopamine D1 receptor; D2R, dopamine D2 receptor; D3R, dopamine D3 receptor; D4R, dopamine D4 receptor; D5R, dopamine D5 receptor; DA, dopamine; DAT, dopamine transporter; DβH, dopamine-β-hydroxylase; DHPG, dihydroxyphenylglycol; DOPAC, 3,4-dihydroxyphenylacetic acid; MAO, monoamine oxidase; mEPSCs, miniature excitatory postsynaptic currents; METH, methamphetamine; NE, norepinephrine; NET, norepinephrine transporter; SERT, serotonin transporter; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; VMAT, vesicular monoamine transporter.
2. Alterations of Monoaminergic Systems in VPA-Induced ASD Models

2.1. Serotonergic Systems

2.1.1. Neural Development of Serotonergic Neurons

In the central nervous system, the majority of serotonergic neurons are localized in the raphe nuclei. All the serotonergic neurons are derived from the developing rhombencephalon. Serotonergic progenitors are generated in the isthmus and p3 domain of the ventral hindbrain. Serotonergic neurons undergo neurogenesis at E9.5–E12 in mice and E10.5–E13 in rats. Shortly after cell mitosis, differentiating serotonergic neurons begin their migration as early as E10 [69]. The early-born neurons migrate to form the anterior cluster of serotonergic neurons (B5–B9) that extensively innervate the forebrain, midbrain, cerebellum, and raphe nuclei themselves. The late-born neurons migrate caudally to form the posterior cluster of serotonergic neurons (B1–B4) that innervate the brainstem and spinal cord [70]. Upon the end of differentiation, serotonergic neurons produce 5-hydroxytryptamine (5-HT, i.e., serotonin) not only for neurotransmission, but also for facilitating the maturation of themselves. Along with axonal outgrowth and navigation, serotonergic neurons start to release 5-HT during axonal outgrowth as early as E16.5. The extensive and prolonged axonal innervations of serotonergic neurons are not completed until several weeks after birth [71].

2.1.2. Neurochemical Properties of Serotonin

Tryptophan is the precursor for the synthesis of serotonin. Tryptophan hydroxylase (TPH), the rate-limiting enzyme found only in serotonergic neurons, converts tryptophan into 5-hydroxytryptophan (5-HTP). Then, aromatic L-amino acid decarboxylase (AADC) converts 5-HTP into 5-HT. Cytoplasmic 5-HT is packed into synaptic vesicles through vesicular monoamine transporter 2 (VMAT2), where it is stored until being released into the synaptic cleft by exocytosis. The neurotransmission activity of 5-HT in the synaptic cleft is terminated by the serotonin transporter (SERT) that reuptakes 5-HT back to presynaptic terminals [70]. Because SERT is critical to 5-HT activity, the kinetics of 5-HT neurotransmission is governed by the level of SERT. 5-HT is metabolically degraded by monoamine oxidase (MAO) and converted into 5-hydroxy-indoleacetaldehyde, which is subsequently oxidized by aldehyde dehydrogenase to derive 5-hydroxyindoleacetic acid (5-HIAA). See Figure 2 for the summary of serotoninergic neurotransmission.

2.1.3. Clinical Evidence of Abnormalities of Serotonergic Systems Related to ASD

Clinical evidence of dysregulated serotonergic systems in ASD patients is yet disputed. The first clinical study has reported hyperserotonemia in early-onset ASD patients [72]. Consistent with this report, a meta-analysis study has revealed elevated levels of 5-HT in the blood of 25.4% of ASD patients [73]. Another group has also reported an increased number of dystrophic 5-HT axons in different regions of human ASD brains [74,75]. Despite the evidence of hyperserotonemia as reported in some clinical studies, postmortem studies indicate different aspects of serotonin dysfunction in ASD pathophysiology. Significant reductions in receptor-binding density of two 5-HT receptors, $\text{G}_i$-coupled $\text{5-HT}_1\alpha$ and $\text{G}_q$-coupled $\text{5-HT}_2$, were found in the posterior cingulate cortex and fusiform gyrus of ASD patients [76]. Moreover, abnormally increased and decreased levels of serotonin receptors were, respectively, observed in ASD patients with and without seizure histories [76]. Age-dependent alterations of the serotonergic systems have recently been identified, especially in the anterior cingulate cortex [77]. In addition to neuroanatomical alterations, genetic linkage studies have observed that SERT variants are correlated with platelet hyperserotonemia and impaired social communication in ASD patients [78–80]. Animal studies have found abnormal serotonergic neurotransmission in ASD-like pathophysiology as well. Normal serotonin levels are critical to the maintenance of E/I balance in cortical neurons, and restoration of serotonin levels can alleviate ASD-like phenotypes [81]. The causal relationship between the ASD-associated SLC6A4/SERT Ala56 coding variant and hyper-
serotonemia has been demonstrated in SLC6A4/SERT Ala56 gain-of-function transgenic mice that exhibited ASD-like behaviors [82].

2.1.4. Abnormalities of Serotonergic Systems in VPA-Induced ASD Models

In the peripheral system, previous studies have found elevated 5-HT levels in serum, plasma or gastrointestinal tract of VPA-treated rodents, which support the general hyper-serotonemia theory of ASD etiology [14,83–85]. However, other studies have reported the reduction in 5-HT-positive cells in the ileum, 5-HT levels and its precursors (tryptophan and 5-HP), and metabolites (5-HIAA) in both the peripheral system and brain [22,86–89]. Note that short-term depletion of 5-HT precursor tryptophan deteriorates repetitive behavior and elevates anxiety status in ASD patients [90]. Given the complexity of clinical case studies, e.g., variations in the genetic, comorbidity, medication, and diet, it remains to be clarified how dysfunction of peripheral 5-HT takes part in ASD pathophysiology.

In the central nervous system, alterations of 5-HT levels have been detected in several brain regions of VPA-treated offspring. Serotonergic neurons of the median raphe nucleus primarily project to the hippocampus, whereas serotonergic neurons of the dorsal raphe nuclei preferentially project to the prefrontal cortex, basal ganglia, and amygdala [70]. In contrast to the more consistent results of VPA-induced 5-HT levels in the regions that are innervated by the dorsal raphe nucleus, the VPA-induced alterations of 5-HT levels are varied in the hippocampus [14,18,83,91,92]. The dorsal and median raphe nuclei may differ in vulnerabilities to VPA treatments. Reduced serotonin receptors have also been found in the hippocampus [93]. In other brain regions, alterations in 5-HT levels are more consistent. In VPA-treated rodents, increased 5-HT levels are detected in the cerebellum and pons; however, reduced 5-HT levels are detected in the prefrontal cortex, midbrain, and amygdala. Considering developmental changes in VPA-treated rodents, administration of VPA during E9-E12.5 is at the time window of neurogenesis, differentiation, and migration of serotonergic neurons in the raphe nuclei. Kuwagata et al. have reported differential vulnerabilities of 5-HT-positive neurons to different time windows of maternal VPA administration. They found abnormal migration of 5-HT-positive neurons in rats receiving VPA at E11, but not in rats receiving VPA at E9 [94]. Wang et al. found an increased number of 5-HT-positive neurons in the raphe magnus nucleus (caudal part of raphe nuclei), but Miyazaki et al. report no significant changes in the total number of 5-HT-positive cells in the raphe nuclei [95,96]. These two studies are different at VPA dose and the timing of VPA injections. The discrepancy of these findings may be partly explained by VPA-induced abnormal migration in the raphe nuclei as reported by other groups [94,95,97]. Abnormal differentiation of serotonergic neurons has been reported in the embryos of VPA-treated zebrafish [98]. Because VPA is an HDAC inhibitor that can regulate chromatin remodeling, it would be of interest to study how VPA-induced epigenetic changes in chromatin remodeling affect the development of serotonergic neurons.

2.1.5. Behavioral Phenotypes Related to Abnormal Serotonergic Systems in VPA-Induced ASD Models

At the functional level, Wang et al. (2018) reported abnormal excitatory/inhibitory balance and mEPSCs of 5-HT neurons in the dorsal raphe nucleus of VPA-treated brains, implicating a role of 5-HT in the modulation of excitatory/inhibitory balance of neuronal activity [46]. With respect to behavioral phenotypes, most of the studies have found abnormal social behaviors along with abnormalities in serotonergic systems [18,22,83,84,86–89,91,92,96,99]. Impaired social communication is a hallmark of ASD symptoms, and defective social interaction also occurs in VPA-induced ASD animals. Other ASD-like behavioral phenotypes in serotonergic deficient VPA mice are increased repetitive behaviors and anxiety levels, abnormal sensation, delayed developmental milestones, and impaired memory [18,83,84,86–89,92,96,99]. By contrast, the findings of locomotion are inconsistent in that some studies have reported reduced locomotion [18,84,86], but other studies found elevated locomotion [87–89,91,92,100]. This inconsistency cannot be explained by species of animals or dosage of VPA. An interesting
finding is that abnormal circadian rhythm and activity were found in rats that maternally received VPA at E9.5. Note that a high proportion of patients with autism show sleep disturbance, especially insomnia [101,102]. Regarding the causality of abnormal serotonergic systems and behavioral abnormalities, Wang et al. (2013) have treated VPA-induced ASD rats with 5-HT$_{1A}$ receptor agonists during behavioral tests. They found that the treatment of 5-HT$_{1A}$ receptor agonists could restore social impairments and improve extinction of fear memory, suggesting that abnormal serotonergic signaling may contribute to abnormal social behaviors and memory deficits in VPA-treated rodents [96]. In the future, more studies are required to further clarify the causal relationship between behavioral phenotypes and serotonergic abnormalities (Table 1).

Table 1. Summary of valproic acid (VPA)-induced teratogenicity in serotonergic systems.

| Monoamines-Related Endophenotypes (Age of Animals during Analysis) | Other Molecular, Cellular and Physiological Phenotypes (Age of Animals during Analysis) | Behavioral Phenotypes (Age of Animals during Analysis) | Animals/ Gender | VPA Exposure | References |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------|--------------|------------|
| ↓ 5-HT in the hippocampus (> 3 m/o)                          | ↑ Inflammation in colonic tissues                                                              | ↓ Social play behavior                                 | Wistar rats/male | 600 mg/kg, E12.5, i.p. | [83]       |
| ↑ 5-HT in serum (P28)                                       | ↓ Tight junction protein (claudin1 and occluding) in the colonic tissues (> 3 m/o)            |                                                        |                 |              |            |
| ↑ Proinflammatory cytokines: IL-17A, TNF-α, IL-6             | ↓ GABA in serum Abnormal gut microbiota                                                       |                                                        |                 |              |            |
| ▼ 5-HT in serum (N/A)                                       | ↑ Anxiety (6 wks)                                                                               |                                                        | C57BL/6 mice/male | 500 mg/kg, E12.5, i.p. | [85]       |
| ↑ 5-HT in the hippocampus, cerebellum, and plasma (P50)     | Altered several metabolic pathways caused by microbial dysbiosis (P21, 28, 35)               |                                                        |                 |              |            |
| ↓ 5-HT and its precursors (L-tryptophan and 5-HTP) and final metabolites (5-HIAA) in the colon, feces, serum, cerebellum, and PFC (8 wks) | ↓ GABA in serum, cerebellum, and PFC                                                           |                                                        |                 |              |            |
| ▼ 5-HT and its precursors (L-tryptophan and 5-HTP) and final metabolites (5-HIAA) in the colon, feces, serum, cerebellum, and PFC (8 wks) | ↑ Glutamate in serum, cerebellum, and PFC                                                      |                                                        |                 |              |            |
| ↓ Acetylcholine in serum and PFC                            | Abnormal gut microbiota                                                                        |                                                        |                 |              |            |
| (8 wks)                                                      | ▼ 5-HT levels and numbers of 5-HT positive cells in the ileum (P28)                           |                                                        |                 |              |            |
| ↓ Novel object recognition                                  | ▼ Social behavior                                                                             |                                                        | Wistar rats/male | 500 mg/kg, E12.5, i.p. | [86]       |
| ▼ Social behavior                                           | ▼ Depression                                                                                  |                                                        |                 |              |            |
| ▼ Depression                                                | ▼ Repetitive behavior                                                                          |                                                        |                 |              |            |
| ▼ Repetitive behavior (8 wks)                               |                                                        |                                                        |                 |              |            |
| ▼ Epithelial loss and intestinal inflammation in the ileum   |                                                        |                                                        |                 |              |            |
| ↑ Neuroinflammation in the dorsal hippocampus (P28)           |                                                        |                                                        |                 |              |            |
| ↓ Social interaction (P28)                                  |                                                        |                                                        | BALB/c mice/both gender | 500 or 600 mg/kg, E11.5, s.c. | [22]       |
| Monoamines-Related Endophenotypes (Age of Animals during Analysis) | Other Molecular, Cellular and Physiological Phenotypes (Age of Animals during Analysis) | Behavioral Phenotypes (Age of Animals during Analysis) | Animals/Gender | VPA Exposure | References |
|---|---|---|---|---|---|
| ↓ 5-HT in the PFC and ileum (P50) | ↓ Gastrointestinal tract motility ↓ Activity of mitochondrial enzyme complex-I, II, V in PFC ↑ BBB permeability ↑ Nitrosative stress (nitrate/nitrite) ↑ Inflammation in the brain and ileum ↑ Calcium (P50) | ↓ Social behaviors (P44, 45) ↓ Exploratory behaviors (P47) ↑ Locomotion (P49) ↑ Repetitive behaviors (P46) ↑ Anxiety (P47, 48) | Wistar rats/male | 500 mg/kg, E12.5, s.c. | [87–89] |
| ↑ 5-HT in the hippocampus (P110) | ↑ Inflammation: ↓ Glutathione and catalase; ↑ Total nitrite ↓ Cerebellar Purkinje cells ↑ Neurodegenerative chromatolysis in the cerebellum (P110) | Developmental delay (P9–12) Impaired nociceptive sensation ↑ Locomotion ↓ Rearing and hole poking ↑ Anxiety ↓ Social behaviors (P90–110) | Rats/male | 600 mg/kg, E12.5, i.p. | [92] |
| ↑ 5-HT in the hippocampus (P40) | ↑ Oxidative stress ↓ Number of Purkinje cell layer in the cerebellum (P40) | ↓ Locomotion ↓ Motor coordination ↓ Spatial learning and memory ↑ Anxiety Impaired nociceptive sensation Delayed negative geotaxis (P40) | BALB/c mice/both gender | 400 mg/kg, P14, s.c. | [18] |
| ↓ 5-HT in the midbrain ↑ 5-HT in the cerebellum and pons (P22) | ↑ Free amino acid in the frontal cortex (P22) | ↓ Social behaviors ↓ Spatial memory (P21) | Albino rats/male | 800 mg/kg, E12.5, oral feeding | [99] |
| ↓ 5-HT in the hippocampus n.s. SERT and 5-HIAA among a variety of brain regions (P50) | | ↑ Locomotion ↓ Social behaviors (P31) | Wistar rats/male | 500 mg/kg, E9, i.p. | [91] |
| ↑ TPH-positive neurons in the raphe magnus nucleus (P28) ↑ SERT binding in the amygdala (P90) | ↑ Amplitude of mEPSC in the lateral amygdala ↓ Paired pulse facilitation ratio in the thalamo-amygdaloid synapses (P35) | ↓ Social behaviors Impaired fear memory extinction (P28–35) | SD rats/male | 500 mg/kg, E12.5, i.p. | [96] |
| ↑ Elevation of 5-HT after feeding in the frontal cortex (P56–105) | | ↑ Locomotion (P18) ↓ Body weight (4 wks) Abnormal circadian rhythm and activity (P28–43) | Wistar rats/both gender | 800 mg/kg, E9.5, oral feeding | [100] |
| ↓ Serotonin receptor, Hirib, HirId, Hir3a mRNA in the hippocampus (P35) | Altered expression in genes encoding cholinergic and adrenergic receptors in the cortex and cerebellum (P35) | N/A | Wistar rats/both gender | 800 mg/kg, E11, oral feeding | [93] |
| ↓ or absent 5-HT neuronal differentiation in embryos (48 and 72 hpf) | Lack of Mauthner neurons ↓ Pronuclear gene ooc1ib (28 and 32 hpf) | N/A | Zebradish/N/A | 0.625 mM, from 50% epiboly to 27 hpf, incubated in normal medium 0.625 mM, from 24 to 48 hpf, incubated in normal medium | [98] |
Table 1. Cont.

| Monoamines-Related Endophenotypes (Age of Animals during Analysis) | Other Molecular, Cellular and Physiological Phenotypes (Age of Animals during Analysis) | Behavioral Phenotypes (Age of Animals during Analysis) | Animals/Gender | VPA Exposure | References |
|---|---|---|---|---|---|
| Abnormal migration of 5-HT in adult dorsal raphe nucleus n.s. in number of 5-HT positive neurons (P50) | ↓ Shh mRNA level at E9 | N/A | Wistar rats/male | 800 mg/kg, E9, oral feeding | [95] |
| Abnormal migration of 5-HT-positive neurons in the pons | Abnormal navigation of 5-HT-positive neurons in the boundary of midbrain and hindbrain (E16) | N/A | SD rats/both gender | 800 mg/kg, E9 or E11, oral feeding | [94] |
| Abnormal 5-HT neurons distribution (dorsal tangential migration) in the rostral raphe nucleus (E15.5) | ↓ Shh mRNA expression around the isthmus (E11.5) | N/A | Wistar rats/both gender | 800 mg/kg, E9.5, oral feeding | [97] |

All the animals in the studies listed in this table received a single administration of VPA. Abbreviations: ↑, increased; ↓, decreased; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine (serotonin); 5-HTP, 5-hydroxytryptophan; BBB, blood–brain barrier; dpf, days post-fertilization; E, embryonic day; GABA, γ-Aminobutyric acid; hpf, hours post-fertilization; Htr, 5-hydroxytryptamine receptors; IL, interleukin; m/o, months old; i.p., intraperitoneal injection; mEPSCs, miniature excitatory postsynaptic currents; N/A, not applicable; P, postnatal day; PFC, prefrontal cortex; s.c., subcutaneous injection; SERT, serotonin transporter; Shh, sonic hedgehog; TH, tyrosine hydroxylase; TNF, tumor necrosis factor; TPH, tryptophan hydroxylase; VPA, valproic acid; wks, weeks old.

2.1.6. Microbiota–Gut–Brain Axis and Serotonergic Systems in VPA-Induced ASD Models

Peripheral 5-HT is mainly produced by enterochromaffin cells from dietary tryptophan in the gastrointestinal tract, and is taken up by platelets or SERT on serotoninergic presynaptic terminals. Peripheral 5-HT regulates gastrointestinal motility and is involved in immune function [103]. An intriguing issue is how peripheral 5-HT affects the central nervous system, given that 5-HT in the central and peripheral nervous systems is separated by the blood–brain barrier. 5-HT may influence enteric nerves, vagal afferent activity, or inflammatory responses, and then modulate the central nervous system indirectly [58]. Another potential mechanism of peripheral 5-HT influence neurodevelopmental process is mediated by the microbiota–gut–brain axis. Previous studies have demonstrated the causal relationship of the microbiota–gut–brain axis and the pathogenesis of ASD, and ~70% of ASD patients show comorbid gastrointestinal disturbances [58]. 5-HT has been shown to modulate bacterial motility and gene expression profile of bacteria in vivo [58,104], indicating complex feedback interactions between 5-HT and microbiota in the gastrointestinal tract. Conversely, the microbiota is known not only to synthesize 5-HT, but also to modulate the serotonergic system in the gastrointestinal tract of the host, suggesting...
that 5-HT may be a communication molecule of gut–brain interactions. In germ-free mice, TPH (rate-limiting enzyme of 5-HT) is upregulated, and the 5-HT level in the hippocampus is reduced with enhanced anxiety [105,106]. Animal studies have found the abnormal composition of microbiota in ASD-like models, including VPA-treated rodents [84–86]. The VPA-treated rodents also showed altered 5-HT, L-tryptophan, 5-HTP, and 5-HIAA levels in serum, colon, feces, cerebellum, and prefrontal cortex [84–86]. Given the important role of the microbiota–gut–brain axis in ASD pathophysiology, it would be of interest to see if the modulation of the gut–brain axis by serotonin may be involved in the etiology of ASD.

2.2. Catecholamines

2.2.1. Neural Development of Catecholaminergic Neurons

DA and norepinephrine (NE) are the primary catecholamines that are released from groups of catecholamine neurons in different brain regions (A1–A17). An additional three adrenaline-containing groups (C1–C3) are distributed in the telencephalon, mesencephalon, and rhombencephalon [107]. Catecholamines are important neurotransmitters that are essential to brain function. Dysfunction of catecholamines is involved in the pathophysiology of neurodevelopmental and neurodegenerative disorders, including ASD and Parkinson’s disease.

Although dopaminergic neurons comprise a small population of neurons in the brain, they profoundly control brain function through the extensive innervations of their network [107]. Among the different groups of dopaminergic neurons, substantia nigra pars compacta (SNC, A9) and ventral tegmental area (VTA, A10) play important roles in the control of motor, reward, motivation, and emotion. Progenitors of dopaminergic neurons are originated from the ventral midline of the floor/basal plate that is located near to the midbrain–hindbrain boundary (MHB), or isthmus. In mice, SNC dopaminergic neurons are generated before E11 and their neurogenesis is peaked at E11–E12, whereas the peak of neurogenesis of VTA dopaminergic neurons occurs at E12–E13 [108]. After exiting the cell cycle progression, midbrain dopaminergic neurons migrate radially and/or tangentially from the ventricular zone toward the pial surface, and this migratory process continues until the first week after birth. [109,110].

On the other hand, cell bodies of norepinephrinergic neurons are clustered in the medulla oblongata, pons, and midbrain. The locus coeruleus (LC) is known as the major source of NE in the brain, which is located near the floor of the fourth ventricle [70]. Progenitors of LC neurons are mainly derived from rhombomere 1, and LC neurons are born early and migrate toward the basal plate before E10.5 [111]. Neurogenesis of norepinephrinergic neurons occurs predominantly between E10.5–E12.5. Norepinephrinergic neurons are functionally active by birth [112], and they gradually mature during postnatal periods [113].

2.2.2. Neurochemical Properties of Catecholamines

All the catecholamines are derived from L-tyrosine. The rate-limiting enzyme, tyrosine hydroxylase (TH), converts L-tyrosine to L-DOPA, and AADC subsequently converts L-DOPA to DA. For neurons that synthesize NE or epinephrine, dopamine-β-hydroxylase catalyzes DA into NE, and phenylethanolamine N-methyltransferase further converts NE into epinephrine. The degradative metabolism of catecholamines is mediated by MAO and catechol-O-methyltransferase (COMT). DA and NE are transported into synaptic vesicles by VMAT2. After being released into the synaptic cleft, NE and DA are recycled back into the presynaptic terminal, respectively, through the uptake by norepinephrine transporter (NET) and dopamine transporter (DAT). The DA receptor family consists of two members, D1-like and D2-like receptors. Activation of D1-like receptor increases cAMP levels, whereas activation of D2-like receptor decreases cAMP levels in DA responsive cells. As for the NE receptor, NE binds to three NE receptor families (α1, α2, β) [70]. See Figure 2 for the summary of catecholaminergic neurotransmission.
2.2.3. Clinical Evidence of Abnormalities of Catecholaminergic Systems Related to ASD

An early study documented dysregulation of catecholamines in ASD patients whose plasma level of NE is increased, but dopamine-β-hydroxylase is decreased [114]. Clinical study has shown reduced DA level in the mPFC of medication-free ASD patients, which suggests an aberrant function of the dopaminergic systems in ASD [115]. Genetic linkage studies have revealed that mutations of many dopaminergic systems regulators are associated with ASD, including dopamine receptor\textit{DRD1} [116], \textit{DRD2} [117], \textit{DRD3} [118], \textit{DRD4} [119], and \textit{DAT} [120,121]. The dopaminergic systems are of particular interest with respect to ASD pathophysiology, because it participates in the reward system that is involved in social motivation and social interaction [122,123]. Because of the multifaceted roles of the dopaminergic systems in reward prediction, decision making, and motivation [124–126] that are affected in ASD patients, it is imperative to study the pathophysiological changes in dopaminergic systems in ASD.

As for the norepinephrinergic systems, previous studies have reported abnormalities of resting-state functional connectivity in LC and elevated tone of NE activity in ASD children [127,128]. Another positron emission tomography study found a correlation between the binding signals of D1R and NET and ASD symptoms [129]. Moreover, antipsychotic drugs targeting NE receptors have been shown to have beneficial effects on ASD symptoms [130].

2.2.4. Abnormalities of Catecholaminergic Systems in VPA-Induced ASD Models

Alterations of dopaminergic systems have been extensively reported in studies of VPA-induced ASD animal models. Reduction in the rate-limiting enzyme of TH has been found in the striatum of VPA-treated rats [131]. The reduced TH level presumably would result in decreased DA level in the striatum. However, another study has reported an elevated DA level in the striatum of VPA-treated mice [132]. In fact, the increased DA levels were found not only in the striatum, but also in the frontal cortex, cerebellum, and pons [14,99,132]. By contrast, decreased DA levels were found in the hippocampus, midbrain, and serum of VPA-treated animals [86,99]. The variations in the changes in DA levels in different brain regions may result from the differences in DA turnover and/or the expression of DA-related signaling molecules in different brain regions, including DA receptor, acetylation of DAT, and phosphorylation of DARPP-32 in response to social stimulus [66,93,133–135]. Along this line, an interesting question is whether the dopaminergic systems may be affected by the external environment. Indeed, elevated DA levels and reduced DA turnover were found in VPA mice raised in different social environments [132].

In the norepinephrinergic systems, reduced NE levels are detected in the hippocampus, midbrain, and serum; whereas increased NE levels are found in the frontal cortex, cerebellum, and pons [84,99]. Furthermore, increased NET expression and acetylation levels have been reported in VPA-treated rats [66]. Regarding VPA-induced changes in neuronal development, abnormal migration of TH-positive neurons have been found in the pons, and the boundary of the midbrain and hindbrain [94], which implicates that pathological changes in the catecholamine systems may result from VPA-induced developmental abnormalities.

2.2.5. Neuroanatomical Phenotypes Related to Altered Catecholamine Systems in VPA-Induced ASD Models

In addition to altered metabolic, abnormal migration, and distribution of TH-positive DA neurons in the SNc and VTA have been found in VPA-treated rats and chickens [94,136]. Regarding dopaminergic projections, a recent study has used the tissue clearing iDISCO method combined with a laser light-sheet confocal microscope to investigate whole-brain dopaminergic axonal projections. Ádám et. al. (2020) have found reduced ventrobasal telencephalic projections from the VTA along with a reduced number of DA neurons in the VTA of VPA-treated mice. By contrast, an increased number of DA neurons in the substantia nigra was observed in VPA-treated mice. These findings suggest region- and cell-type
specificity in VPA-induced pathophysiology and further suggest potential compensatory mechanisms among different dopaminergic neuronal populations in the midbrain [137].

2.2.6. Behavioral Phenotypes Related to Altered Catecholamine Systems in VPA-Induced ASD Models

At the behavioral level, consistent behavioral phenotypes have been found along with catecholaminergic abnormalities in VPA-treated rodents, including reduced social behaviors, increased repetitive, depressive and anxious behaviors, and impaired memory [14,66,84,86,93,99,131,133,134,138]. Impaired cognitive flexibility and temporal processing have also been observed in VPA-treated rodents, implicating abnormal functions of the prefrontal cortex [131,132]. Reduced levels of hyperlocomotion in response to methamphetamine further support the abnormalities of dopaminergic systems in VPA-treated mice [135]. Risperidone and aripiprazole are two atypical antipsychotics for alleviating ASD syndromes in VPA-treated mice, including impairments in social behaviors, vocalization, and recognition memory [64,65]. Note that risperidone inhibits D2R and 5-HT<sub>2A</sub> receptors, whereas aripiprazole acts as an agonist of 5-HT<sub>2A</sub> receptor and also as a partial agonist of D2R. The causality between dopaminergic and behavioral phenotypes awaits further investigation. On the other hand, hyperactivity, repetitive behaviors, impaired social interaction, and recognition memory can be alleviated by atomoxetine, a blocker of NET. The neurochemical mechanisms by which altered catecholaminergic systems contribute to ASD pathogenesis require further studies.

2.2.7. Altered Reciprocal Interactions of Microbiota and Catecholamine Systems in VPA-Induced ASD Models

Decreased levels of DA and NE in serum have been found in VPA-treated rats along with the abnormal composition of gut microbiota [84,86]. NE has been shown to regulate various aspects of bacteria, from bacterial growth, migration to the gene expression profile of bacteria [58]. Some bacteria are found to express monoamine transporter on their plasma membrane [139]. Other bacteria can convert host-derived inactive forms of NE and DA into biologically active forms [140], suggesting a role of microbiota in modulating the activity of catecholaminergic systems. The mechanisms underlying reciprocal interactions between peripheral catecholaminergic systems and microbiota–gut–brain axis and how dysfunctional microbiota–gut–brain axis affect central catecholaminergic systems await future studies.

2.3. Histamine

2.3.1. Neural Development of Histaminergic Neurons

In the postnatal stages, histaminergic neurons are mainly distributed in the tuberomammillary nucleus of the hypothalamus, and they extensively innervate a variety of brain regions, including the cerebral cortex, hippocampus, preoptic area, striatum, and thalamus [141]. Histidine decarboxylase (HDC) is an enzyme that catalyzes the decarboxylation of histidine to form histamine. Neurogenesis of HDC-positive neurons in the tuberomammillary nucleus begins from E13-18 and is peaked at E16 in the rat brain [142]. Notably, there is a transient histaminergic system during prenatal brain development. Transient histamine-immunoreactive neurons are located in the mesencephalon, metencephalon, and rhombencephalon, and they are no longer detected at the end of embryonic stages in the rat brain. The peak of neurogenesis in the brain and the highest level of histamine coincide at ~E14, implicating a potential role of histamine in regulating neurogenesis in the rat brain [143]. Later studies have revealed a regulatory role of histamine in promoting neural proliferation, cell-type specific differentiation, and axogenesis [143]. It has also been reported that histamine systems can cross-talk with other neurotransmitter systems by forming heteroreceptors (see below) and by other unknown mechanisms. For example, the expression levels of dopamine, D2R, and D3R are increased in HDC knockout mice [144,145].
2.3.2. Neurochemical Properties of Histamine

The histaminergic systems play important roles in modulating the sleep–wake cycle, reward, neuroinflammation, emotion, and learning and memory [146]. Histamine is converted from L-histidine by histidine decarboxylase (HDC), and is packaged into synaptic vesicles by VMAT2 before releasing. Although there are no high-affinity reuptake mechanisms for uptaking histamine, histamine N-methyltransferase (HNMT) is responsible for the clearance of histamine in the synaptic cleft [70,141]. In the brain, neuronal expression of histamine receptor H1 (H1R), histamine receptor H2 (H2R), and histamine receptor H3 (H3R) are engaged in the regulation of different neurological functions. For example, H1R and H3R signalings are important for regulating the sleep–wake cycle, whereas H2R signaling is involved in aggression [147].

2.3.3. Clinical Evidence of Abnormalities of Histaminergic Systems Related to ASD

Clinical studies have linked abnormal histaminergic systems to ASD pathogenesis. Human postmortem brain study has found increased HNMT levels and histamine receptors in the dorsolateral prefrontal cortex of ASD patients [148], suggestive of altered histaminergic systems in ASD pathophysiology. The histaminergic system transiently but profoundly affects the developmental processes of other neural systems, including serotonergic and dopaminergic systems [144,149]. Furthermore, histamine not only modulates the proliferation and differentiation of neural stem cells, but also regulates the biological functions of astrocytes and microglia that are involved in neuroinflammation [144,149]. Taken together, histaminergic dysfunction may contribute to autistic abnormalities either directly as a neuromodulator or indirectly through affecting neuronal development (Table 2).

| Monoamines-Related Endophenotypes (Age of Animals during Analysis) | Other Molecular, Cellular, and Physiological Phenotypes (Age of Animals during Analysis) | Behavioral Phenotypes (Age of Animals during Analysis) | Animals | VPA Exposure | References |
|---|---|---|---|---|---|
| Catecholaminergic Systems: Dopamine and Norepinephrine | | | | | |
| ↓ TH immunoreactivity in the striatum (P30) | ↓ Vocalization (P11) | N/A | Wistar rats/male | 400 mg/kg, E12.5, i.p. | [131] |
| ↓ Dopamine β-Hydroxylase (5 dpf and 6 mpf) | ↓ Locomotion in larvae (5 dpf) | N/A | Zebrafish/male | 25 µM, from 10 hpf to 24 hpf, incubated in embryonic medium | [150] |
| ↓ DOPAC (5 dpf and 6 mpf) | ↓ GABA in serum, cerebellum and PFC | | | | |
| ↓ NE (5 dpf and 6 mpf) | ↓ Glutamate in serum, cerebellum and PFC | | | | |
| | ↑ Acetylcholine in serum and PFC | | | | |
| | Abnormal gut microbiota (8 wks) | | | | |
| | ▼ DA in serum (8 wks) | ▼ GABA in serum, cerebellum and PFC | | 500 mg/kg, E12.5, i.p. | [86] |
Table 2. Cont.

| Monoamines-Related Endophenotypes (Age of Animals during Analysis) | Other Molecular, Cellular, and Physiological Phenotypes (Age of Animals during Analysis) | Behavioral Phenotypes (Age of Animals during Analysis) | Animals | VPA Exposure | References |
|---------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------|---------|--------------|-----------|
| ↑ DA in the frontal cortex (P50)                             | N/A                                                                             | N/A                                                    | SD rats/male | 800 mg/kg, E9, oral feeding | [14]    |
| ↓ DA level in the dorsal striatum (DOPAC/DA) in the dorsal striatum (1 day after behavioral test) | N/A                                                                             | Abnormal temporal processing (P60)                     | CrlFcen:CF1 mice/both gender | 600 mg/kg, E12.5, s.c. | [132] |
| ↓ DA in the hippocampus and midbrain                         | ↑ Free amino acid in the frontal cortex (P22)                                   | ↓ Social behaviors                                     | Albino rats/male | 800 mg/kg, E12.5, oral feeding | [99]    |
| ↑ DA in the frontal cortex, cerebellum and pons              | ↓ Social behaviors (P21)                                                        |                                                       |          |              |           |
| ↓ NE in the hippocampus and the midbrain                     | ↑ c-fos immunoreactivity in the piriform cortex                                  | ↓ Social behaviors (8 wks)                             | CrlFcen:CF1 mice/male | 600 mg/kg, E12.5, s.c. | [138] |
| ↑ NE in frontal cortex, cerebellum and pons (P22)            | ↑ PPARα in the VTA                                                              | ↓ Repetitive behavior                                  | SD rats/both gender | 500 mg/kg, E12.5, i.p. | [133] |
| ↓ DARPP-32 phosphorylation in response to social stimulus in the nucleus accumbens (P60) | ↑ Vglut and Vglut/Vgat ratio in the caudate-putamen of male mice                  | Delayed negative geotaxis                              |          |              |           |
|                                                                  | ↓ PSD95 expression in the caudate-putamen of male mice                           | ↓ Social behaviors                                     |          |              |           |
|                                                                  | ↑ NR2B in the caudate-putamen of male mice                                      | ↑ Repetitive behavior                                  |          |              |           |
|                                                                  | (P60)                                                                           | ↑ Depression in male mice                               |          |              |           |
|                                                                  | (P48–53)                                                                        | ↑ Anxiety                                               |          |              |           |
| ↑ D1R in the nucleus accumbens and hippocampus (P35–40 and P90–95) | ↓ Resting potential of medium spiny neurons in the striatum                   | ↓ Social behaviors n.s. amphetamine-induced hyperlocomotion (P35–40) | Wistar rats/male | 500 mg/kg, E12.5, i.p. | [134] |
| ↓ Drd1a mRNA in the cerebellum                               | Altered expression in genes encoding cholinergic and adrenergic receptors in the cortex and cerebellum | N/A                                                    | Wistar rats/both gender | 800 mg/kg, E11, oral feeding | [93]    |
| Monoamines-Related Endophenotypes (Age of Animals during Analysis) | Other Molecular, Cellular, and Physiological Phenotypes (Age of Animals during Analysis) | Behavioral Phenotypes (Age of Animals during Analysis) | Animals | VPA Exposure | References |
|---|---|---|---|---|---|
| ↓ NE in serum (P28) | ↑ Proinflammatory cytokines: IL-17A, TNF-α, IL-6 ↓ GABA in serum | Delayed developmental milestones (P2–21) ↓ Locomotion ↓ Social behaviors ↑ Repetitive behavior (P28) | Wistar rats/male | 600 mg/kg, E12.5, i.p. | [84] |
| ↑ DAT expression and acetylation of histone H3 bound to Slc6a3 gene in the PFC ↑ NET expression and acetylation of histone H3 bound to Slc6a2 gene in the PFC (4 wks) | Hyperactivity ↑ Repetitive rearing (4 wks) | SD rats/male | 400 mg/kg, E12, s.c. | [66] |
| ↓ D1R and D2R in the prefrontal cortex ↓ METH-induced DA release in the prefrontal cortex (8 wks) | ↓ c-fos positive neurons in the prefrontal cortex after METH administration (8 wks) | ICR mice/male | 500 mg/kg, E12.5, i.p. | [135] |
| Abnormal migration of TH-positive neurons in the pons Abnormal navigation of TH-positive neurons in the boundary of midbrain and hindbrain (E16) | Disorganization of cortical lamination (E16) | N/A | SD rats/both gender | 800 mg/kg, E9 or E11, oral feeding | [94] |
| Abnormal distribution of TH-positive neurons in substantia nigra and VTA ↓ DRD1 and GRIN2A expression in the septum (P2) | N/A | Chicken (Gallus gallus) (N/A) | N/A | Chicken (Gallus gallus) (N/A) | 35 µmoles, E14, dropping VPA solution into the air sac | [136] |
| ↓ Widening TH-positive mesotelecephalic axonal fascicles ↓ TH-positive cells in the VTA ↓ TH-positive terminals in ventrobasal telencephalic region ↑ TH-positive cells in the substantia nigra (P7) | N/A | C57BL/6/both gender | N/A | C57BL/6/both gender | 400 mg/kg, E13.5, s.c. | [137] |
2.3.4. Abnormalities in the Histaminergic System in VPA-Induced ASD Models

Similar to what is observed in clinical studies, abnormalities in the histaminergic system have been found in VPA-induced ASD-like animal models as well. Reduced levels of histamine receptor H3 (H3R), HDC and histaminergic neurons have been found in VPA-treated zebrafish [150]. Notably, H3R antagonists have therapeutic effects on VPA-treated mice in reducing inflammation and ASD-like behaviors [151–153]. H3R antagonists also alleviate ASD-like symptoms in other ASD animal models [154,155]. Given that Gi-coupled H3R can indirectly modulate other neurotransmitter systems by forming heteroreceptors, the involvement of histaminergic systems in ASD pathophysiology may have been underestimated. Until now, there is no study revealing alterations of histaminergic systems except VPA-treated zebrafish. No information is yet available for potential changes in the central and peripheral systems in mammals.

Histamine is not only synthesized in the central nervous system, but also in the peripheral mast cells and gastric enterochromaffin-like cells that play important roles in the microbiota–gut–brain axis [58]. Moreover, some microbiota in the gastrointestinal tract of the host also synthesize histamine. Although histamine hardly penetrates the blood–brain barrier, in addition to the microbiota–gut–brain axis, histamine may indirectly affect the nervous system via the immune system and the vagal system [58,156]. It is worthwhile to note that histamine is a key player in many immune responses, because maternal immune activation is a risk factor for offspring to develop ASD [56]. It is imperative to decipher the mechanisms by which histamine by itself and/or through regulating other neurotransmission systems contribute to the pathophysiology of ASD.

3. Conclusions

Over the decades of studies, the VPA-induced ASD-like animal models have provided important information about the pathophysiology of ASD. The monoaminergic systems, key players of neuromodulation in the brain, are extensively affected in the pathophysiology of ASD as demonstrated in the VPA-induced ASD model. In this review, we summarize and discuss the pathological changes in monoaminergic systems related to ASD etiology. Given the pharmacological nature of VPA that can regulate cellular signaling as well as chromatin remodeling as an HDAC inhibitor, the information gained from VPA model studies with respect to monoaminergic systems would not only help clarify the pathogenic trajectories of...
ASD at the cellular and epigenetic levels, but it may also help develop therapeutic reagents for ASD [37].

**Author Contributions:** H.-Y.K. and F.-C.L. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This review was supported by the Ministry of Science and Technology-Taiwan grants MOST110-2636-B-A49-001, MOST111-2636-B-A49-007 (H.-Y.K.), MOST107-2320-B-010-041-MY3, MOST110-2320-B-A49A-532-MY3, MOST111-2321-B-001-011, MOST110-2326-B-A49A-504, and Featured Areas Research Center Program Grant from the Ministry of Education-Taiwan (F.-C.L.).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Maenner, M.J.; Shaw, K.A.; Baio, J.; Washington, A.; Patrick, M.; DiRienzo, M.; Wiggins, L.D.; Pettygrove, S.; Andrews, J.G.; et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016. MMWR. Surveill. Summ. 2020, 69, 1–12. [CrossRef]

2. Association, A.P. Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 5th ed.; American Psychiatric Publishing: Arlington, VA, USA, 2013.

3. Bourgeron, T. From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat. Rev. Neurosci. 2015, 16, 551–563. [CrossRef] [PubMed]

4. Guang, S.; Pang, N.; Deng, X.; Yang, L.; He, F.; Wu, L.; Chen, C.; Yin, F.; Peng, J. Synaptopathology involved in autism spectrum disorder. Front. Cell. Neurosci. 2018, 12, 470. [CrossRef] [PubMed]

5. Möhrle, D.; Fernández, M.; Peñagarikano, O.; Frick, A.; Allman, B.; Schmid, S. What we can learn from a genetic rodent model about autism. Neurosci. Biobehav. Rev. 2020, 109, 29–53. [CrossRef]

6. Modabbernia, A.; Velthorst, E.; Reichenberg, A. Environmental risk factors for autism: An evidence-based review of systematic reviews and meta-analyses. Mol. Autism 2017, 8, 13. [CrossRef]

7. Ximenes, J.C.M.; Verde, E.C.L.; da Graça Naffah-Mazzacoratti, M.; de Barros Viana, G.S. Valproic acid, a drug with multiple molecular targets related to its potential neuroprotective action. Neurosci. Mol. 2012, 3, 107–123. [CrossRef]

8. Christensen, J.; Gromborg, T.K.; Sørensen, M.J.; Schendel, D.; Parner, E.T.; Pedersen, L.H.; Vestergaard, M. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309, 1696–1703. [CrossRef] [PubMed]

9. Zhao, H.; Wang, Q.; Yan, T.; Zhang, Y.; Xu, H.J.; Yu, H.P.; Tu, Z.; Guo, X.; Jiang, Y.H.; Li, X.J.; et al. Maternal valproic acid exposure leads to neurogenesis defects and autism-like behaviors in non-human primates. Transl. Psychiatry 2019, 9, 267. [CrossRef]

10. Mimura, K.; Oga, T.; Sasaki, T.; Nakagaki, K.; Sato, C.; Sumida, K.; Hoshino, K.; Saiito, K.; Miyawaki, I.; Suhara, T.; et al. Abnormal axon guidance signals and reduced interhemispheric connection via anterior commissure in neonates of marmoset ASD model. Neuroimage 2019, 195, 243–251. [CrossRef]

11. Binkerd, P.E.; Rowland, J.M.; Nau, H.; Hendrickx, A.G. Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam. Appl. Toxicol. 1998, 41, 485–493. [CrossRef]

12. Roullet, F.I.; Lai, J.K.; Foster, J.A. In utero exposure to valproic acid and autism—a current review of clinical and animal studies. Neurotoxicol. Teratol. 2013, 36, 47–56. [CrossRef] [PubMed]

13. Rodier, P.M.; Ingram, J.L.; Tisdale, B.; Nelson, S.; Romano, J. Embryological origin for autism: Developmental anomalies of the cranial nerve motor nuclei. J. Comp. Neurol. 1996, 370, 247–261. [CrossRef]

14. Narita, N.; Kato, M.; Tazoe, M.; Miyazaki, K.; Narita, M.; Okado, N. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: Putative animal models for autism. Peiadiatr. Res. 2002, 50, 576–579. [CrossRef] [PubMed]

15. Kim, K.C.; Kim, P.; Go, H.S.; Choi, C.S.; Yang, S.I.; Choeg, J.H.; Shin, C.Y.; Ko, K.H. The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. Toxicol. Lett. 2011, 201, 137–142. [CrossRef]

16. Wagner, G.C.; Reuhl, K.R.; Cheh, M.; McRae, P.; Halladay, A.K. A new neurobehavioral model of autism in mice: Pre- and postnatal exposure to sodium valproate. J. Autism Dev. Disord. 2006, 36, 779–793. [CrossRef] [PubMed]

17. Yochum, C.L.; Dowling, P.; Reuhl, K.R.; Wagner, G.C.; Ming, X. VPA-induced apoptosis and behavioral deficits in neonatal mice. Brain Res. 2008, 1203, 126–132. [CrossRef] [PubMed]

18. Pragnya, B.; Kameshwari, J.S.; Veeresh, B. Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. Behav. Brain Res. 2014, 270, 86–94. [CrossRef]

19. Schneider, T.; Roman, A.; Basta-Kaim, A.; Kubera, M.; Budziszewska, B.; Schneider, K.; Przewlocki, R. Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 2008, 33, 728–740. [CrossRef]
20. Kazlauskas, N.; Seifte, A.; Campolongo, M.; Zappala, C.; Depino, A.M. Sex-specific effects of prenatal valproic acid exposure on sociability and neuroinflammation: Relevance for susceptibility and resilience in autism. *Psychoneuroendocrinology* 2019, 110, 104441. [CrossRef]

21. Thornton, A.M.; Humphrey, R.M.; Kerr, D.M.; Finn, D.P.; Roche, M. Increasing endocannabinoid tone alters anxiety-like and stress coping behaviour in female rats prenatally exposed to valproic acid. *Molecules* 2021, 26, 3720. [CrossRef]

22. De Theije, C.G.; Koelink, P.J.; Korte-Bouws, G.A.; Lopes da Silva, S.; Korte, S.M.; Olivier, B.; Garssen, J.; Kraneveld, A.D. Intestinal inflammation in a murine model of autism spectrum disorders. *Brain. Behav. Immun.* 2014, 37, 240–247. [CrossRef]

23. Mowery, T.M.; Wilson, S.M.; Kostylev, P.V.; Dina, B.; Buchholz, J.B.; Prieto, A.L.; Garraghty, P.E. Embryological exposure to valproic acid disrupts morphology of the deep cerebellar nuclei in a sexually dimorphic way. *Int. J. Dev. Neurosci.* 2015, 40, 15–23. [CrossRef] [PubMed]

24. Konopko, M.A.; Denmore, A.L.; Krueger, B.K. Sexually dimorphic epigenetic regulation of brain-derived neurotrophic factor in fetal brain in the valproic acid model of autism spectrum disorder. *Dev. Neurosci.* 2017, 39, 507–518. [CrossRef] [PubMed]

25. Roux, S.; Bailly, Y.; Bossu, J.L. Regional and sex-dependent alterations in Purkinje cell density in the valproate mouse model of autism. *NeuroReport* 2019, 30, 82–88. [CrossRef]

26. Cho, H.; Kim, C.H.; Knight, E.Q.; Oh, H.W.; Park, B.; Kim, D.G.; Park, H.J. Changes in brain metabolic connectivity underlie autistic-like social deficits in a rat model of autism spectrum disorder. *Sci. Rep.* 2017, 7, 13213. [CrossRef]

27. Melancia, F.; Schiavi, S.; Servadio, M.; Cartocci, V.; Campolongo, P.; Palmeiry, M.; Pallottini, V.; Trezza, V. Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling. *Br. J. Pharmacol.* 2018, 175, 3699–3712. [CrossRef]

28. Anshu, K.; Nair, A.K.; Kumaresan, U.D.; Kutty, B.M.; Srinath, S.; Laxmi, T.R. Altered attentional processing in male and female rats in a prenatal valproic acid exposure model of autism spectrum disorder. *Autism Res.* 2017, 10, 1929–1944. [CrossRef]

29. Gu, Y.Y.; Han, Y.; Liang, J.J.; Cui, Y.N.; Zhang, B.; Zhang, Y.; Zhang, S.B.; Qin, J. Sex-specific differences in the gut microbiota and fecal metabolites in an adolescent valproic acid-induced rat autism model. *Front. Biosci. (Landmark Ed.)* 2021, 26, 1585–1598. [CrossRef] [PubMed]

30. Li, X.; Large, C.H.; Ricci, R.; Taylor, J.J.; Nahas, Z.; Bohning, D.E.; Morgan, P.; George, M.S. Using interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (fMRI) and dynamic causal modeling to understand the discrete circuit specific changes of medications: Lamotrigine and valproic acid changes in motor or prefrontal effective connectivity. *Psychiatry Res. Neuroimaging* 2011, 194, 141–147. [CrossRef]

31. Wandschneider, B.; Koepp, M.J. Pharmacokinetic MR imaging of the brain: Determining the functional anatomy of the effects of medication. *Neuroimage Clinical* 2016, 12, 691–697. [CrossRef]

32. Meador, K.; Reynolds, M.W.; Crean, S.; Fahrbach, K.; Probst, C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. *Epilepsia Res.* 2008, 81, 1–13. [CrossRef] [PubMed]

33. Frisch, C.; Hüsch, K.; Angenstein, F.; Kudin, A.; Kunz, W.; Elger, C.E.; Helmstaedter, C. Dose-dependent memory effects and cerebral volume changes after in utero exposure to valproate in the rat. *Epilepsia* 2009, 50, 1432–1441. [CrossRef] [PubMed]

34. Favre, M.; Barkat, T.; Mendola, D.; Khazen, G.; Markram, H.; Markram, K. General developmental health in the VPA-rat model of autism. *Front. Cell. Neurosci.* 2013, 7, 88. [CrossRef] [PubMed]

35. Nicolini, C.; Fahnestock, M. The valproic acid-induced rodent model of autism. *Exp. Neurol.* 2018, 299, 217–227. [CrossRef] [PubMed]

36. Mast, T.J.; Cukierski, M.A.; Nau, H.; Hendrickx, A.G. Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. *Toxicology* 1986, 39, 111–119. [CrossRef]

37. Kuo, H.Y.; Liu, F.C. Molecular pathology and pharmacological treatment of autism spectrum disorder-like phenotypes using rodent models. *Front. Cell. Neurosci.* 2018, 12, 422. [CrossRef] [PubMed]

38. Rosenberg, G. The mechanisms of action of valproate in neuropsychiatric disorders: Can we see the forest for the trees? *Cell. Mol. Life Sci.* 2007, 64, 2090–2103. [CrossRef]

39. Hussman, J.P. Letters to the editor: Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. *J. Autism Dev. Disord.* 2001, 31, 247–248. [CrossRef]

40. Rubenstein, J.I.; Merzenich, M.M. Model of autism: Increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav.* 2003, 2, 255–267. [CrossRef]

41. Kim, J.W.; Park, K.; Kang, R.J.; Gonzales, E.L.T.; Kim, D.G.; Oh, H.A.; Seung, H.; Ko, M.J.; Kwon, K.J.; Kim, K.C.; et al. Pharmacological modulation of AMPA receptor rescues social impairments in animal models of autism. *Neuropsychopharmacology* 2018, 44, 314–323. [CrossRef]

42. Wu, H.F.; Chen, Y.J.; Chu, M.C.; Hsu, Y.T.; Lu, T.Y.; Chen, I.T.; Chen, P.S.; Lin, H.C. Deep brain stimulation modified autism-like deficits via the serotonin system in a valproic acid-induced rat model. *Int. J. Mol. Sci.* 2018, 19, 2840. [CrossRef]

43. Rinaldi, T.; Silberberg, G.; Markram, H. Hyper-connectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid. *Cerebral. Cortex.* 2008, 18, 763–770. [CrossRef]

44. Rinaldi, T.; Perrodin, C.; Markram, H. Hyper-connectivity and hyper-plasticity in the medial prefrontal cortex in the valproic Acid animal model of autism. *Front. Neural Circ.* 2008, 2, 4. [CrossRef]
45. Rinaldi, T.; Kulongara, K.; Antoniello, K.; Markram, H. Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc. Natl. Acad. Sci. USA 2007, 104, 13501–13506. [CrossRef] [PubMed]

46. Wang, R.; Hausknrecht, K.; Shen, R.Y.; Haj-Dahmane, S. Potentiation of glutamatergic synaptic transmission onto dorsal raphe serotonergic neurons in the valproic acid model of autism. Front. Pharmacol. 2018, 9, 1185. [CrossRef] [PubMed]

47. Taleb, A.; Lin, W.; Xu, X.; Zhang, G.; Zhou, Q.G.; Naveed, M.; Meng, F.; Fukunaga, K.; Han, F. Emerging mechanisms of valproic acid-induced neurotoxic events in autism and its implications for pharmacological treatment. Biomed. Pharmacother. 2021, 137, 111322. [CrossRef]

48. Chomiak, T.; Hu, B. Alterations of neocortical development and maturation in autism: Insight from valproic acid exposure and animal models of autism. Neurotoxicol. Teratol. 2013, 36, 57–66. [CrossRef] [PubMed]

49. Ryu, Y.K.; Park, H.Y.; Go, J.; Choi, D.H.; Choi, Y.K.; Rhee, M.; Lee, C.H.; Kim, K.S. Sodium phenylbutyrate reduces repetitive self-grooming behavior and rescues social and cognitive deficits in mouse models of autism. Psychopharmacology 2021, 238, 1833–1845. [CrossRef] [PubMed]

50. Kataoka, S.; Takuma, K.; Haru, Y.; Maeda, Y.; Ago, Y.; Matsuda, T. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. Int. J. Neuropsychopharmacol. 2011, 14, 91–103. [CrossRef]

51. Moldrich, R.X.; Leangae, G.; She, D.; Dolan-Evans, E.; Nelson, M.; Reza, N.; Reutens, D.C. Inhibition of histone deacetylase in utero causes sociability deficits in postnatal mice. Behav. Brain Res. 2013, 257, 253–264. [CrossRef]

52. Watanabe, S.; Kurotani, T.; Oga, T.; Noguchi, J.; Isoda, R.; Nakagami, A.; Sakai, K.; Nakagaki, K.; Sumida, K.; Hoshino, K.; et al. Functional and molecular characterization of a non-human primate model of autism spectrum disorder shows similarity with the human disease. Nat. Commun. 2021, 12, 5388. [CrossRef]

53. Olde Loohuis, N.F.M.; Martens, G.J.M.; van Bokhoven, H.; Kaplan, B.B.; Homberg, J.R.; Aschrafi, A. Prevention or amelioration of autism-like symptoms in animal models: Will it bring us closer to treating human ASD? Trends Pharmacol. Sci. 2021, 42, 979–987. [CrossRef] [PubMed]

54. Barret, C.E.; Hennessey, T.M.; Gordon, K.M.; Ryan, S.J.; McNair, M.L.; Ressler, K.J.; Rainnie, D.G. Developmental disruption of amygdala transcriptome and socioemotional behavior in rats exposed to valproic acid prenatally. Mol. Autism 2017, 8, 42. [CrossRef] [PubMed]

55. Lin, J.; Zhang, K.; Cao, X.; Zhao, Y.; Ullah Khan, N.; Liu, X.; Tang, X.; Chen, M.; Zhang, H.; Shen, L. iTRAQ-based proteomics analysis of rat cerebral cortex exposed to valproic acid before delivery. ACS Chem. Neurosci. 2022. [CrossRef]

56. Careaga, M.; Murai, T.; Bauman, M.D. Maternal immune activation and autism spectrum disorder: From rodents to nonhuman and human primates. Biol. Psychiatry 2017, 81, 391–401. [CrossRef] [PubMed]

57. Kern, J.K.; Geier, D.A.; Sykes, L.K.; Geier, M.R. Relevance of neuroinflammation and encephalitis in autism. Front. Cell. Neurosci. 2015, 9, 519. [CrossRef]

58. Cryan, J.F.; O’Riordan, K.J.; Cowan, C.S.M.; Sandhu, K.V.; Bastiaansen, T.F.S.; Boehme, M.; Codagnone, M.G.; Cussotto, S.; Fulling, C.; Golubeva, A.V.; et al. The microbiota-gut-brain axis. Physiol. Rev. 2019, 99, 1877–2013. [CrossRef] [PubMed]

59. Tung, E.W.; Winn, L.M. Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: A role for oxidative stress in valproic acid-induced neural tube defects. Mol. Pharmacol. 2011, 80, 979–987. [CrossRef] [PubMed]

60. Mabunga, D.F.; Gonzales, E.L.; Kim, J.W.; Kim, K.C.; Shin, C.Y. Exploring the validity of valproic acid animal model of autism. Exp. Neurol. 2015, 24, 285–300. [CrossRef]

61. Ergaz, Z.; Weinstein-Fudim, L.; Ornoy, A. Genetic and non-genetic animal models for autism spectrum disorders (ASD). Reprod. Toxicol. 2016, 64, 116–140. [CrossRef]

62. Spooren, W.; Lindemann, L.; Ghosh, A.; Santarelli, L. Synapse dysfunction in autism: A molecular medicine approach to drug discovery in neurodevelopmental disorders. Trends Pharmacol. Sci. 2012, 33, 669–684. [CrossRef] [PubMed]

63. Ornoy, A.; Weinstein-Fudim, L.; Ergaz, Z. Prevention or amelioration of autism-like symptoms in animal models: Will it bring us closer to treating human ASD? Int. J. Mol. Sci. 2019, 20, 1074. [CrossRef] [PubMed]

64. Kuo, H.Y.; Liu, F.C. Valproic acid induces aberrant development of striatal compartments and cortico striatal pathways in a mouse model of autism spectrum disorder. EASEB J. 2011, 31, 4458–4471. [CrossRef]

65. Hara, Y.; Ago, Y.; Taruta, A.; Hasebe, S.; Kawase, H.; Tanabe, W.; Tsukada, S.; Nakazawa, T.; Hashimoto, H.; Matsuda, T.; et al. Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice. Int. J. Neuropsychopharmacol. 2017, 20, 91–103. [CrossRef] [PubMed]

66. Choi, C.S.; Hong, M.; Kim, K.C.; Kim, J.W.; Yang, S.M.; Seung, H.; Ko, M.J.; Choi, D.H.; You, J.S.; Shin, C.Y.; et al. Effects of atomoxetine on hyper-locomotive activity of the prenatally valproate-exposed rat offspring. Biomol. Ther. 2014, 22, 406–413. [CrossRef]

67. Chaliha, D.; Albrecht, M.; Vaccarezza, M.; Takechi, R.; Lam, V.; Al-Salami, H.; Mamo, J. A systematic review of the valproic-acid-induced rodent model of autism. Dev. Neurosci. 2020, 42, 12–48. [CrossRef] [PubMed]
Biomedicines 2022, 10, 560

94. Kuwagata, M.; Ogawa, T.; Shioda, S.; Nagata, T. Observation of fetal brain in a rat valproate-induced autism model: A systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2014, 24, 919–929. [CrossRef]

74. Azmitia, E.C.; Singh, J.S.; Whitaker-Azmitia, P.M. Increased serotonin axons (immunoreactive to 5-HT transporter) in postmortem brains from young autism donors. Neuropharmacology 2011, 60, 1347–1354. [CrossRef] [PubMed]

93. Zieminska, E.; Ruszczynska, A.; Augustyniak, J.; Toczylowska, B.; Lazarewicz, J.W. Zinc and copper brain levels and expression of neurotransmitter receptors in two rat ASD models. Mol. Psychiatry 2004, 9, 264–271. [CrossRef]

89. Kumar, H.; Sharma, B.M.; Sharma, B. Benefits of agomelatine in behavioral, neurochemical and blood brain barrier alterations in rats exposed prenatally to valproic acid. Front. Mol. Neurosci. 2016, 6, e1603001. [CrossRef] [PubMed]

69. Hawthorne, A.L.; Wylie, C.J.; Landmesser, L.T.; Deneris, E.S.; Silver, J. Serotonergic neurons migrate radially through the neuroepithelium by dynamin-mediated somal translocation. J. Neurosci. 2010, 30, 420. [CrossRef]

70. Brady, S. Basic Neurochemistry: Molecular, Cellular and Medical Aspects; Elsevier: Amsterdam, The Netherlands, 2005.

71. Deneris, E.; Gaspar, P. Serotonin neuron development: Shaping molecular and structural identities. Wiley Interdiscip. Rev. Dev. Biol. 2018, 7, e301. [CrossRef]

72. Schain, R.J.; Freedman, D.X. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J. Pediatr. 1961, 58, 315–320. [CrossRef]

73. Gabriele, S.; Sacco, R.; Persico, A.M. Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2014, 24, 919–929. [CrossRef]

75. Azmitia, E.C.; Singh, J.S.; Hou, X.P.; Wegiel, J. Dystrophic serotonin axons in postmortem brains from young autism patients. Anat. Res. 2011, 294, 1653–1662. [CrossRef]

68. Obal, A.; Gibbs, T.T.; Blatt, G.J. Reduced serotonin receptor subtypes in a limbic and a neocortical region in autism. Autism Res. 2013, 6, 571–583. [CrossRef]

76. Oblak, A.; Gibbs, T.T.; Blatt, G.J. Differential serotonin transporter (5-HTT) and 5-HT(2) receptor density in limbic and neocortical areas of adults and children with autism spectrum disorders: Implications for selective serotonin reuptake inhibitor efficacy. J. Neurochem. 2019, 151, 642–659. [CrossRef]

77. Brandenburg, C.; Blatt, G.J. Variants of the serotonin transporter gene (SLC6A4) significantly contribute to hyperserotonemia in autism. Mol. Psychiatry 2004, 9, 151–161. [CrossRef]

80. Nakai, N.; Nagano, M.; Saitow, F.; Watanabe, Y.; Kawamura, Y.; Kawamoto, A.; Tamada, K.; Mizuma, H.; Onoe, H.; Watanabe, Y.; et al. Serotonin rebalances cortical tuning and behavior linked to autism symptoms in 15q11-13 CNV mice. Sci. Adv. 2016, 2, e1501741. [CrossRef] [PubMed]

81. Nakai, N.; Nagano, M.; Saitow, F.; Watanabe, Y.; Kawamura, Y.; Kawamoto, A.; Tamada, K.; Mizuma, H.; Onoe, H.; Watanabe, Y.; et al. Serotonin rebalances cortical tuning and behavior linked to autism symptoms in 15q11-13 CNV mice. Sci. Adv. 2016, 2, e1501741. [CrossRef] [PubMed]

82. Veenstra-VanderWeele, J.; Muller, C.L.; Iwamoto, H.; Sauer, J.E.; Owens, W.A.; Shah, C.R.; Cohen, J.; Mannangatti, P.; Jessen, T.; et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc. Natl. Acad. Sci. USA 2012, 109, 5469–5474. [CrossRef]

83. Wang, J.; Zheng, B.; Zhou, D.; Xing, J.; Li, H.; Li, J.; Zhang, Z.; Zhang, B.; Li, P. Supplementation of diet with different n-3/n-6 PUFA ratios ameliorates autistic behavior, reduces serotonin, and improves intestinal barrier impairments in a valproic acid rat model of autism. Front. Psychiatry 2020, 11, 552345. [CrossRef] [PubMed]

84. Qi, Z.; Lyu, M.; Yang, L.; Yuan, H.; Cao, Y.; Zhai, L.; Dang, W.; Liu, J.; Yang; F.; Li, Y. A novel and reliable rat model of autism. Front. Psychiatry 2021, 12, 549810. [CrossRef] [PubMed]

85. Lim, J.S.; Lim, M.Y.; Choi, Y.; Ko, M. Modeling environmental risk factors of autism in mice induces IBD-related gut microbial dysbiosis and hyperserotonemia. Mol. Brain 2017, 10, 14. [CrossRef] [PubMed]

86. Kong, Q.; Wang, B.; Tian, P.; Li, X.; Zhao, J.; Zhang, H.; Chen, W.; Wang, G. Daily intake of Lactobacillus alleviates autistc-like behaviors by ameliorating the 5-hydroxytryptamine metabolic disorder in VPA-treated rats during weaning and sexual maturation. Food Funct. 2021, 12, 2591–2604. [CrossRef]

87. Kumar, H.; Sharma, B. Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats. Brain Res. Bull. 2016, 124, 27–39. [CrossRef]

88. Kumar, H.; Sharma, B. Minocycline ameliorates prenatal valproic acid induced autistic behavior, biochemistry and blood brain barrier impairments in rats. Brain Res. 2016, 1630, 89–97. [CrossRef]

89. Kumar, H.; Sharma, B.M.; Sharma, B. Benefits of agomelatine in behavioral, neurochemical and blood brain barrier alterations in prenatal valproic acid induced autism spectrum disorder. Neurochem. Int. 2015, 91, 34–45. [CrossRef]

90. McDougle, C.J.; Naylor, S.T.; Cohen, D.J.; Aghajanian, G.K.; Heninger, G.R.; Price, L.H. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch. Gen. Psychiatry 1996, 53, 993–1000. [CrossRef]

91. Dufour-Rainfray, D.; Vourc’h, P.; Le Guisquet, A.M.; Garreau, L.; Terrant, D.; Bodard, S.; Jaumain, E.; Guilhan, Z.; Belzung, C.; Andres, C.R.; et al. Behavior and serotonergic receptors in rats exposed prenatally to valproate: A model for autism. Neurosci. Lett. 2010, 470, 55–59. [CrossRef]

92. Sandhya, T.; Sovjanyya, J.; Veeresh, B. Bacopa monniera (L.) Wetstt ameliorates behavioral alterations and oxidative markers in sodium valproate induced autism in rats. Neurochem. Res. 2012, 37, 1121–1131. [CrossRef]

93. Zieminska, E.; Ruszczyńska, A.; Augustyniak, J.; Toczyłowska, B.; Lazarewicz, J.W. Zinc and copper brain levels and expression of neurotransmitter receptors in two rat ASD models. Front. Mol. Neurosci. 2021, 14, 656740. [CrossRef] [PubMed]

94. Kuwagata, M.; Ogawa, T.; Shioda, S.; Nagata, T. Observation of fetal brain in a rat valproate-induced autism model: A developmental neurotoxicity study. Int. J. Dev. Neurosci. 2009, 27, 399–405. [CrossRef] [PubMed]
95. Miyazaki, K.; Narita, N.; Narita, M. Maternal administration of thalidomide or valproic acid causes abnormal serotoninergic neurons in the offspring: Implication for pathogenesis of autism. *Int. J. Dev. Neurosci.* 2005, 23, 287–297. [CrossRef] [PubMed]

96. Wang, C.C.; Lin, H.C.; Chan, Y.H.; Gean, P.W.; Yang, Y.K.; Chen, P.S. 5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model. *Int. J. Neuropsychopharmacol.* 2013, 16, 2027–2039. [CrossRef] [PubMed]

97. Oyabu, A.; Narita, M.; Tashiro, Y. The effects of prenatal exposure to valproic acid on the initial development of serotoninergic neurons. *Int. J. Dev. Neurosci.* 2013, 31, 202–208. [CrossRef]

98. Jacob, J.; Ribes, V.; Moore, S.; Constable, S.C.; Sastri, N.; Gerety, S.S.; Martin, D.J.; Sergeant, C.P.; Wilkinson, D.G.; Briscoe, J. Valproic acid silencing of ascl1b/Ascl1 results in the failure of serotoninergic differentiation in a zebrafish model of fetal valproate syndrome. *Dis. Model. Mech.* 2014, 7, 107–117. [CrossRef]

99. Ali, E.H.; Elgozy, A.H. Combined prenatal and postnatal butyl paraben exposure produces autism-like symptoms in offspring: Comparison with valproic acid autistic model. *Pharmacol. Biochem. Behav.* 2013, 111, 102–110. [CrossRef]

100. Tsujino, N.; Nakatani, Y.; Seki, Y.; Nakasato, A.; Nakamura, M.; Sugawara, M.; Arita, H. Abnormality of circadian rhythm genes and pathways to autism spectrum disorder. *Neurochem. Int.* 2010, 56, 32, 18, 187–206. [CrossRef]

101. Lai, M.C.; Lombardo, M.V.; Baron-Cohen, S. Autism. *Lancet* 2014, 383, 896–910. [CrossRef]

102. Lord, C.; Elsabbagh, M.; Baird, G.; Veenstra-Vanderweele, J. Autism spectrum disorder. *Lancet* 2018, 392, 508–520. [CrossRef]

103. Namkung, J.; Kim, H.; Park, S. Peripheral serotonin: A new player in systemic energy homeostasis. *Biomedicines* 2022, 103. [CrossRef]

104. Hettinger, J.A.; Liu, X.; Schwartz, C.E.; Michaelis, R.C.; Holden, J.J. A DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 2008, 147, 628–636. [CrossRef]

105. Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsiao, E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell* 2015, 161, 264–276. [CrossRef]

106. Crumeyrolle-Arias, M.; Jaglin, M.; Bruneau, A.; Vancassel, S.; Cardona, A.; Daugé, V.; Naudon, L.; Rabot, S. Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. *Psychoneuroendocrinology* 2014, 42, 207–217. [CrossRef]

107. Bjorklund, A.; Dunnett, S.B. Dopamine neuron systems in the brain: An update. *Trends Neurosci.* 2007, 30, 194–202. [CrossRef] [PubMed]

108. Bayer, S.A.; Wills, K.V.; Triarhou, L.C.; Ghetti, B. Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons. *Exp. Brain Res.* 1995, 105, 191–199. [CrossRef] [PubMed]

109. Prakash, N.; Wurst, W. Development of dopaminergic neurons in the mammalian brain. *Cell. Mol. Life Sci.* 2006, 63, 187–206. [CrossRef] [PubMed]

110. Crumeyrolle-Arias, M.; Jaglin, M.; Bruneau, A.; Vancassel, S.; Cardona, A.; Daugé, V.; Naudon, L.; Rabot, S. Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. *Psychoneuroendocrinology* 2014, 42, 207–217. [CrossRef]

111. Nakamura, S.; Kimura, F.; Sakaguchi, T. Postnatal development of electrical activity in the locus ceruleus. *J. Comp. Neurol.* 2006, 496, 802–818. [CrossRef]

112. Poe, G.R.; Foote, S.; Eschenko, O.; Johansen, J.P.; Bouret, S.; Aston-Jones, G.; Harley, C.W.; Manahan- Vaughan, D.; Weinshenker, D.; Valentino, R.; et al. Locus coeruleus: A new look at the blue spot. *J. Comp. Neurol.* 2006, 496, 802–818. [CrossRef]

113. Nakamura, S.; Kimura, F.; Sakaguchi, T. Postnatal development of electrical activity in the locus ceruleus. *J. Neuropsychopharmacol.* 2012, 37, 510–524. [CrossRef]

114. Lake, C.R.; Ziegler, M.G.; Murphy, D.L. Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. *Arch. Gen. Psychiatry* 1977, 34, 553–566. [CrossRef] [PubMed]

115. Ernst, M.; Zameckin, A.J.; Matochik, J.A.; Pascualvaca, D.; Cohen, R.M. Low medial prefrontal dopaminergic activity in autistic children. *Lancet* 1997, 350, 638. [CrossRef] [PubMed]

116. Hettinger, J.A.; Liu, X.; Schwartz, C.E.; Michaelis, R.C.; Holden, J.J. A DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 2008, 147, 628–636. [CrossRef]

117. Hettinger, J.A.; Liu, X.; Hudson, M.L.; Lee, A.; Cohen, I.L.; Michaelis, R.C.; Schwartz, C.E.; Lewis, S.M.; Holden, J.J. DRD2 and PPP1R1B (DARPP-32) polymorphisms independently confer increased risk for autism spectrum disorders and additively predict affected status in male-only affected sib-pair families. *Behav. Brain Funct.* 2012, 8, 19. [CrossRef]

118. De Krom, M.; Staal, W.G.; Ophoff, R.A.; Hendriks, J.; Buitelaar, J.; Franke, B.; de Jonge, M.V.; Bolton, P.; Collier, D.; Curran, S. A common variant in DRD3 receptor is associated with autism spectrum disorder. *Biol. Psychiatry* 2009, 65, 625–630. [CrossRef] [PubMed]

119. Gadow, K.D.; Devincenzi, C.J.; Olvet, D.M.; Pisarevskaya, V.; Hatchwell, E. Association of DRD4 polymorphism with severity of oppositional defiant disorder, separation anxiety disorder and repetitive behaviors in children with autism spectrum disorder. *Eur. J. Neuropsychopharmacol.* 2010, 20, 1058–1065. [CrossRef]

120. Hamilton, P.J.; Campbell, N.G.; Sharma, S.; Erreger, K.; Herborg Hansen, F.; Saunders, C.; Belovich, A.N.; Consortium, N.A.A.S.; Sahai, M.A.; Cook, E.H.; et al. De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. *Mol. Psychiatry* 2013, 18, 1315–1323. [CrossRef]

121. Nguyen, M.; Roth, A.; Kyzar, E.J.; Poudel, M.K.; Wong, K.; Stewart, A.M.; Kaluuff, A.V. Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD). *Neurochem. Int.* 2014, 66, 15–26. [CrossRef]
122. Dichter, G.S.; Damiano, C.A.; Allen, J.A. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: Animal models and clinical findings. J. Neurodev. Disord. 2012, 4, 19. [CrossRef]
123. Gunaydin, L.A.; Deisseroth, K. Dopaminergic dynamics contributing to social behavior. Cold Spring Harb. Symp. Quant. Biol. 2014, 79, 221–227. [CrossRef] [PubMed]
124. Matsumoto, M.; Hikosaka, O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature 2009, 459, 837–841. [CrossRef] [PubMed]
125. Itano, A.; Kesner, A.J.; Keller, K.L.; Stuber, G.D.; Bonci, A.; Ikemoto, S. Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion. J. Neurosci. 2014, 34, 817–822. [CrossRef] [PubMed]
126. Lerner, T.N.; Shiylansky, C.; Davidson, T.J.; Evans, K.E.; Beier, K.T.; Zalocusky, K.A.; Crow, A.K.; Malenka, R.C.; Luo, L.; Tomer, R.; et al. Intact-brain analyses reveal distinct information carried by SNC dopamine subcircuits. Cell 2015, 162, 635–647. [CrossRef] [PubMed]
127. Keehn, B.; Kadlaskar, G.; Bergmann, S.; McNally Keehn, R.; Francis, A. Attentional disengagement and the locus coeruleus–norepinephrine system in children with autism spectrum disorder. Front. Integr. Neurosci. 2021, 15, 716447. [CrossRef]
128. Huang, Y.; Yu, S.; Wilson, G.; Park, J.; Cheng, M.; Kong, X.; Lu, T.; Kong, J. Altered extended locus coeruleus and ventral tegmental area networks in boys with autism spectrum disorder: A resting-state functional connectivity study. Neuropsychiatr. Dis. Treat. 2021, 17, 1207–1216. [CrossRef]
129. Kubota, M.; Fujino, J.; Tei, S.; Takahata, K.; Matsuoka, K.; Tagai, K.; Sano, Y.; Yamamoto, Y.; Shimada, H.; Takado, Y.; et al. Binding of dopamine D1 receptor and noradrenaline transporter in individuals with autism spectrum disorder: A PET study. Cereb. Cortex 2020, 30, 6458–6468. [CrossRef]
130. Beversdorf, D.Q. The role of the noradrenergic system in autism spectrum disorders, implications for treatment. Semin. Pediatr. Neurol. 2020, 35, 100834. [CrossRef]
131. Cezar, L.C.; Kirsten, T.B.; da Fonseca, C.C.N.; de Lima, A.P.N.; Bernardi, M.M.; Felicio, L.F. Zinc as a therapy in a rat model of autism. J. Comp. Neurol. 2014, 513, 387–400. [CrossRef] [PubMed]
132. Acosta, J.; Campolongo, M.A.; Hocht, C.; Depino, A.M.; Golombek, D.A.; Agostino, P.V. Deficits in temporal processing in mice prenatally exposed to valproic acid. Eur. J. Neurosci. 2018, 47, 619–630. [CrossRef]
133. Scheggi, S.; Guzzi, F.; Braccagni, G.; De Montis, M.G.; Parenti, M.; Gambarana, C. Targeting PPARα in the rat ventral tegmental area networks in boys with autism spectrum disorder: A resting-state functional connectivity study. Neuropsychiatr. Dis. Treat. 2021, 17, 1207–1216. [CrossRef]
134. Schiavi, S.; Iezzi, D.; Manduca, A.; Leone, S.; Melancia, F.; Carbone, C.; Petrella, M.; Maniaion, G.; Masi, A.; Trezza, V. Reward-related behavioral, neurochemical and electrophysiological changes in a rat model of autism based on prenatal exposure to valproic acid. Front. Cell. Neurosci. 2019, 13, 479. [CrossRef] [PubMed]
135. Hara, Y.; Takuma, K.; Takano, E.; Katashiba, K.; Taruta, A.; Higashino, K.; Hashimoto, H.; Ago, Y.; Matsuda, T. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model. Behav. Brain Res. 2015, 289, 39–47. [CrossRef] [PubMed]
136. Adiletta, A.; Pross, A.; Taricco, N.; Sgadò, N.; Hara, Y.; Takuma, K.; Takano, E.; Katashiba, K.; Taruta, A.; Higashino, K.; Hashimoto, H.; Ago, Y.; Matsuda, T. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model. Behav. Brain Res. 2015, 289, 39–47. [CrossRef] [PubMed]
137. Adiletta, A.; Pross, A.; Taricco, N.; Sgadò, N.; Hara, Y.; Takuma, K.; Takano, E.; Katashiba, K.; Taruta, A.; Higashino, K.; Hashimoto, H.; Ago, Y.; Matsuda, T. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model. Behav. Brain Res. 2015, 289, 39–47. [CrossRef] [PubMed]
138. Campolongo, M.; Kazlauskas, N.; Falasco, G.; Urrutia, L.; Salgueiro, N.; Hocht, C.; Depino, A.M. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model. Behav. Brain Res. 2015, 289, 39–47. [CrossRef] [PubMed]
139. Campolongo, M.; Kazlauskas, N.; Falasco, G.; Urrutia, L.; Salgueiro, N.; Hocht, C.; Depino, A.M. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model. Behav. Brain Res. 2015, 289, 39–47. [CrossRef] [PubMed]
140. Campolongo, M.; Kazlauskas, N.; Falasco, G.; Urrutia, L.; Salgueiro, N.; Hocht, C.; Depino, A.M. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model. Behav. Brain Res. 2015, 289, 39–47. [CrossRef] [PubMed]
141. Scammell, T.E.; Jackson, A.C.; Franks, N.P.; Wisden, W.; Dauvilliers, Y. Histamine: Neural circuits and new medications. Sleep 2019, 42, zsy183. [CrossRef]
142. Reiner, P.B.; Semba, K.; Fibiger, H.C.; McGeer, E.G. Ontogeny of histidine-decarboxylase-immunoreactive neurons in the tuberomammillary nucleus of the rat hypothalamus: Time of origin and development of transmitter phenotype. J. Comp. Neurol. 1988, 276, 304–311. [CrossRef]
143. Molina-Hernández, A.; Díaz, N.F.; Arias-Montaño, J.A. Histamine in brain development. J. Neurochem. 2012, 122, 872–882. [CrossRef] [PubMed]
144. Carthy, E.; Ellender, T. Histamine, neuroinflammation and neurodevelopment: A review. Front. Neurosci. 2021, 15, 870. [CrossRef] [PubMed]
145. Baldan, L.C.; Williams, K.A.; Gallezot, J.D.; Pogorelov, V.; Rapanelli, M.; Crowley, M.; Anderson, G.M.; Loring, E.; Gorczyca, R.; Billingslea, E.; et al. Histidine decarboxylase deficiency causes tourette syndrome: Parallel findings in humans and mice. Neuron 2014, 81, 77–90. [CrossRef] [PubMed]
146. Haas, H.L.; Sergeeva, O.A.; Selbach, O. Histamine in the nervous system. Physiol. Rev. 2008, 88, 1183–1241. [CrossRef] [PubMed]
147. Naganuma, F.; Nakamura, T.; Yoshikawa, T.; Iida, T.; Miura, Y.; Kárpáti, A.; Matsuzawa, T.; Yanai, A.; Mogi, A.; Mochizuki, T.; et al. Histamine N-methyltransferase regulates aggression and the sleep-wake cycle. Sci. Rep. 2017, 7, 15899. [CrossRef]

148. Wright, C.; Shin, J.H.; Rajpurohit, A.; Deep-Soboslay, A.; Collado-Torres, L.; Brandon, N.J.; Hyde, T.M.; Kleinman, J.E.; Jaffe, A.E.; Cross, A.J.; et al. Altered expression of histamine signaling genes in autism spectrum disorder. Transl. Psychiatry 2017, 7, e1126. [CrossRef]

149. Panula, P.; Sundvik, M.; Karlstedt, K. Developmental roles of brain histamine. Trends Neurosci. 2014, 37, 159–168. [CrossRef]

150. Baronio, D.; Puttonen, H.A.J.; Sundvik, M.; Semenova, S.; Lehtonen, E.; Panula, P. Embryonic exposure to valproic acid affects the histaminergic system and the social behaviour of adult zebrafish (Danio rerio). Br. J. Pharmacol. 2018, 175, 797–809. [CrossRef]

151. Eissa, N.; Jayaprakash, P.; Azimullah, S.; Ojha, S.K.; Al-Houqani, M.; Jalal, F.Y.; Lazewska, D.; Kiec-Kononowicz, K.; Sadek, B. The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism. Sci. Rep. 2018, 8, 13077. [CrossRef]

152. Baronio, D.; Gonchoroski, T.; Castro, K.; Zanatta, G.; Gottfried, C.; Riesgo, R. Histaminergic system in brain disorders: Lessons from the translational approach and future perspectives. Ann. Gen. Psychiatry 2014, 13, 34. [CrossRef]

153. Eissa, N.; Azimullah, S.; Jayaprakash, P.; Jayaraj, R.L.; Reiner, D.; Ojha, S.K.; Beiram, R.; Stark, H.; Łazewska, D.; Kiec-Kononowicz, K.; et al. The dual-active histamine H3 receptor antagonist and acetylcholine esterase inhibitor E100 alleviates autistic-like behaviors and oxidative stress in valproic acid induced autism in mice. Int. J. Mol. Sci. 2020, 21, 3996. [CrossRef] [PubMed]

154. Eissa, N.; Jayaprakash, P.; Stark, H.; Lazewska, D.; Kiec-Kononowicz, K.; Sadek, B. Simultaneous blockade of histamine H3 receptors and inhibition of acetylcholine esterase alleviate autistic-like behaviors in BTBR T+ tf/J mouse model of autism. Biomolecules 2020, 10, 1251. [CrossRef] [PubMed]

155. Molenhuis, R.T.; Hutten, L.; Kas, M.J.H. Histamine H3 receptor antagonism modulates autism-like hyperactivity but not repetitive behaviors in BTBR T+Ipr3tf/J inbred mice. Pharmacol. Biochem. Behav. 2022, 212, 173304. [CrossRef] [PubMed]

156. Alstadhaug, K.B. Histamine in migraine and brain. Headache 2014, 54, 246–259. [CrossRef]